Genetic Technologies Asian Operations Established in Hainan

Genetic Technologies Limited (ASX:GTG) a provider of world-leading genetic risk assessment test products, announced that it has now established its Asian operations within the Hainan Resort Software Community (“HRSC”) Free Trade Zone.

Participants in the Hainan Medical Pilot Zone gain access to the Chinese healthcare market

As a part of the HRSC, Genetic Technologies will receive assistance in obtaining China FDA approval for the Company’s new and growing portfolio of genetic risk assessment tests, dramatically fast-tracking the ‘pathway to sales’ process. In addition, as a part of the HRSC, the Company can take advantage of significant tax benefits, subsidies, and facilitated investment.

HRSC market entry support includes:

  • Marketing assistance – providing a link with government sectors, hospitals and other Chinese based health enterprises
  • Obtaining test samples to undertake new product development specifically for the Chinese ethnic population
  • Chinese corporate registry support
  • Office space in the Free Trade Zone precinct and complimentary accommodation for GTG staff
  • Provision of a Dedicated HRSC Business Development Director (Mr York Yin)

“The Hainan Provincial Government has established a world-class technology zone in Hainan, and we are delighted that Genetic Technologies has joined the medical pilot precinct,” Mr Yin said.

HRSC is owned by China Electronics Corporate (CEC), a State-Owned Enterprise of the China Central Government. The companies approved to operate in China as part of the Hainan Free Trade Zone Initiative can take advantage of significant tax benefits, subsidies, and facilitated investment.

Dr Paul Kasian, Genetic Technologies’ Chairman and CEO, said, “The establishment of operations in Hainan China is a significant step to advance the adoption of genetic risk assessment tests in China and in due course other parts of Asia. We are grateful for the support we have received from HRSC to date and acknowledge their commitment to continue to work with GTG to provide a meaningful contribution to the Healthy China 2030 Policy.”

The establishment of operations follows on from the formal invitation to Genetic Technologies from the Hainan Provincial Government (as announced to the market on 14 August 2018). This announcement referred to the Company forming a joint venture with Zishan for its China initiative; however, the joint venture approach will not be progressing at this time. Instead, Genetic Technologies, through its 100% owned subsidiary HAGT, will work to introduce its world-class genetic risk assessment tests to the Chinese market.

Dr Kasian said, “This is likely to include partnering with Chinese health and medical distribution companies and CFDA accredited genetic testing laboratory operations. The HRSC team will help us find appropriate collaboration partners in mainland China. We hope that Genetic Technologies’ growing suite of world-leading genetic risk assessment test products will become central to China’s future preventative medicine activities.”

The Chinese Healthcare market has an estimated value in excess of US$925 billion – Statista Statistics Portal 2017


Dr Paul Kasian
Chairman and Interim CEO
Genetic Technologies
+61 3 8412 7000

Mr Paul Viney
COO, CFO and Company Secretary
Genetic Technologies
+ 61 438 072 616

Investor Relations and Media – Australia
Karinza Phoenix
+61 428 981 074

Investor Relations and Media – USA
Mr Dave Gentry
Office: 1.800.RED.CHIP (733-2447) 
Cell: 407.491.4498

About Genetic Technologies Limited

Genetic Technologies is a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class.  For more information, please visit and

Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit